(02) 9850 4000
GlyTherix
  • Home
  • Company
    • Financial Statements
  • Product Pipeline
  • For Investors
  • News
  • Contact Us
Select Page
GlyTherix and The University of Queensland join forces in ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals

GlyTherix and The University of Queensland join forces in ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals

by GlyTherix | Sep 8, 2022

GlyTherix Ltd today announces that it has been jointly awarded a $4.8 million Australian Research Council (ARC) grant to establish a new Industrial Transformation Research Program (ITRP) Hub as part of a consortium of applicants led by The University of Queensland....
GlyTherix Awarded $3 Million Co-operative Research Centre Project Grant

GlyTherix Awarded $3 Million Co-operative Research Centre Project Grant

by GlyTherix | Jul 16, 2020

16th July 2020: Sydney • Project boasts a dream team of world class partners across antibody manufacturing and clinical trials • Grant will support development of national capability in manufacture and distribution of radioimmuno-oncology drugs • GlyTherix’s...
Four New Peer Reviewed Papers Underline the Strength of the GlyTherix  Technology

Four New Peer Reviewed Papers Underline the Strength of the GlyTherix Technology

by GlyTherix | May 19, 2020

Tuesday 19th May 2020: Sydney GlyTherix Ltd (GlyTherix) is pleased to report publication of four new peer reviewed papers covering both basic science as well as pre-clinical studies around our proprietary novel target, Glypican-1 and our lead antibody to this target,...

ENQUIRIES

Address
Suite 2, Ground Floor, 75 Talavera Road, Macquarie Park, NSW 2113, Australia

Phone
Intl: +612 9850 4000
Aust: 02 9850 4000
(Compare your time zone with Sydney here)

Recent Posts

  • GlyTherix Ltd signs Lutetium-177 supply agreement with ANSTO
  • GlyTherix seeks USD 10M in pre-IPO funding ahead of planned listing in 2024
  • GlyTherix and Adcendo Announce Agreement for Development of Antibody Drug Conjugate

RECENT POSTS

  • GlyTherix Ltd signs Lutetium-177 supply agreement with ANSTO
  • GlyTherix seeks USD 10M in pre-IPO funding ahead of planned listing in 2024
  • GlyTherix and Adcendo Announce Agreement for Development of Antibody Drug Conjugate
  • GlyTherix and The University of Queensland join forces in ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals

ENQUIRIES

Address
Suite 2, Ground Floor, 75 Talavera Road, Macquarie Park, NSW 2113, Australia

Phone
Intl: +612 9850 4000
Aust: 02 9850 4000
(Compare your time zone with Sydney here)

MORE INFO

FOR SHAREHOLDERS:
Shareholder Communications Options

Would you like to talk with Glytherix about:

  • Investing in us?
  • Partnering with us?
  • Media events?
  • Some feedback?
  • Home
  • News
  • Terms of Use
  • Privacy Policy
  • Contact Us

COPYRIGHT 2023 | GLYTHERIX - ALL RIGHTS RESERVED